More Than 100 Combination Cancer Immunotherapies Are Under Clinical Trials In China As Per Kuick Research Report Findings.
More Than 100 Combination Cancer Immunotherapies Are Under Clinical Trials In China As Per Kuick Research Report Findings
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
- Global Combination Cancer Immunotherapy Market Opportunity: > USD 12 Billion
- Combination Cancer Immunotherapy Market By Different Cancers
- Patent, Price & Dosage Analysis On Approved Combination Drugs
- Global & Regional Sales Insights On Approved Combination Drugs Till 2028
- Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
- Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
- Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
Owing to the large population, the Chinese market has provided substantial revenue following US and Europe. Cancer is one of the leading causes of deaths in China, and therefore the cancer drug industry is one of the fastest growing markets in the China. The industry actively invests in research and development activities to identify new potential treatment with high efficiency and can be easily accessible to all patients. Amid all cancer therapeutics, immunotherapy has gained the maximum investment which is mainly due to its high efficacy and specificity in the management of disease. The Chinese government body has approved several immunotherapeutic approaches across wide range of therapeutic indications.
The further research activities in this segment have identified its role in combination therapy. The combination of two or more therapeutic treatment to specifically target cancer inducing or cell sustaining pathways has remain as cornerstone in cancer therapy. Although monotherapy approaches is most commonly used modality for cancer therapies for many different forms of cancer, this conventional method is generally less effective in comparison to combination therapies. The combination therapy works in additive manner, and therefore leads to low therapeutic dosage or reduced cycles of the drugs. Given their promising role in targeting the multifactorial nature of cancer, drug regulatory body in China has granted approval to several novel combination immunotherapies.
For instance in 2022, Shanghai Junshi Biosciences has recently announced that China National Medical Products Administration (NMPA) has approved supplemental new drug application (sNDA) for toripalimab in combination with paclitaxel and cisplatin in the first line treatment of patients with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). Apart from this, CStone Pharmaceuticals and Pfizer also announced NMPA approval of sugemalimab (Cejemly) in combination with pemetrexed and carboplatin as first line of treatment with metastatic non-squamous NSCLC.
China represents one of the most attractive pharmaceutical investment destinations in Asia Pacific region which is mainly due to rising geriatric population, a well-established manufacturing industry, and favorable government policies. Apart from international players, several domestic players have also emerged as prominent player in the research and development market. In recent times, there has been increase in number of deals where Chinese companies develop and commercialize the novel drugs developed by western companies and where multinational companies will commercialize Chinese drug outside China. Apart from this, several deals to utilize each other novel technology or drugs to develop more efficient therapy have also been signed.
One such example is collaboration between Innovent Biologics and NeoCura which aims to access the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of sintilimab in combination with NEO_PLIN2101 across various cancer patients. Further, Asieris Pharmaceuticals entered into collaboration with BeiGene to evaluate the safety and efficacy of oral ALP-2102 in combination with tiselizumab as neoadjuvant therapy in patients with muscle invasive bladder cancer. The company is planning to submit IND application in China to conduct phase-I/II study with primary objectives including safety and recommended phase-II dose.
The China combination cancer immunotherapy market is anticipated to grow with high CAGR rates during the forecast period and is expected to surpass US$ 720 Million by 2028. The rise in prevalence of various cancers, ageing population, westernized diet, shift to sedentary lifestyle, and surge in tobacco smoke exposure due to urbanization in China are the key factors that drive the growth of cancer and thus boosting the growth of China combination cancer immunotherapy market. The presence of robust clinical pipeline of drugs which are expected to enter the market will also boos the growth of market during the forecast period.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com